Fudan-Zhangjiang Bio-Pharma invests ¥210m in SPD Bank structured deposit

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced its subscription to an SPD Bank Structured Deposit Product, investing ¥210 million of its self-owned idle funds. The agreement, effective October 10, 2025, is a principal-guaranteed product with a floating return and is considered low-risk by SPD Bank.

The 76-day product has an expected annualized return rate ranging from 0.70% to 2.04%, linked to the EUR/USD exchange rate. The company states this move aims to enhance overall capital gain and aligns with its objective to safeguard capital and ensure liquidity, anticipating higher returns compared to fixed-term deposits.

The transaction is a disclosable transaction under Chapter 14 of the Listing Rules, as applicable percentage ratios exceed 5% but are below 25%. It is subject to reporting and announcement requirements but is exempt from shareholders' approval. The agreement specifies a formula for calculating returns based on the subscription amount, actual annualized return rate, and investment days.

While the company has no right of early termination, SPD Bank reserves the right under specific circumstances. The directors consider the agreement to be on normal commercial terms, fair, reasonable, and in the best interest of the company and its shareholders.